BFC Planning’s Lantern Pharma LTRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.8K Buy
3,760
+500
+15% +$1.2K ﹤0.01% 2795
2026
Q2
$13.6K Buy
3,260
+500
+18% +$1.47K ﹤0.01% 2206
2026
Q1
$3.78K Hold
2,760
– – ﹤0.01% 2412
2025
Q4
$8.36K Hold
2,760
– – ﹤0.01% 2143
2025
Q3
$12K Hold
2,760
– – ﹤0.01% 1822
2025
Q2
$8.72K Buy
2,760
+1,000
+57% +$3.38K ﹤0.01% 1872
2025
Q1
$6.23K Buy
1,760
+150
+9% +$622 ﹤0.01% 1947
2024
Q4
$5.14K Hold
1,610
– – ﹤0.01% 2015
2024
Q3
$5.91K Buy
+1,610
New +$6.63K ﹤0.01% 1953

Other funds holding LTRN

BFC Planning's LTRN Position: Q3 2026 in Review

BFC Planning increased its Lantern Pharma (LTRN) stake by 15% in Q3 2026, buying an estimated $1.2K and bringing the position to 3,760 shares worth $3.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2795.

BFC Planning first reported a position in LTRN in Q3 2024 and has held it in 9 quarters since. The position peaked at $13.6K in Q2 2026. 36 funds tracked by Wall St. Rank hold LTRN as of Q3 2026.

  • BFC Planning held 3,760 shares of Lantern Pharma worth $3.8K as of Q3 2026.
  • BFC Planning bought 500 Lantern Pharma shares in Q3 2026, an estimated $1.2K.
  • Lantern Pharma made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2795 holding.
  • BFC Planning first reported a position in Lantern Pharma in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Lantern Pharma position peaked at $13.6K in Q2 2026.
  • 36 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.